{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:13:51Z","timestamp":1784945631418,"version":"3.55.0"},"reference-count":48,"publisher":"Impact Journals, LLC","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2022,11,15]]},"DOI":"10.18632\/aging.204355","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T19:53:42Z","timestamp":1667332422000},"page":"8729-8744","source":"Crossref","is-referenced-by-count":6,"title":["Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK\/T-cell lymphoma receiving sequential chemotherapy and radiation"],"prefix":"10.18632","volume":"14","author":[{"given":"Fei","family":"Qi","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","article-title":"NK-\/T-cell lymphomas.","volume":"3","author":"Liang","year":"2021","journal-title":"Leukemia"},{"key":"2","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.11406\/rinketsu.58.2188","article-title":"2016 revision of the WHO classification of lymphoid neoplasms.","volume":"5","author":"Tamaru","year":"2017","journal-title":"Rinsho Ketsueki"},{"key":"3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccell.2020.02.009","article-title":"Breaking Down the Barriers to Define and Treat NK\/T Cell Lymphoma.","volume":"3","author":"Weinstock","year":"2020","journal-title":"Cancer Cell"},{"key":"4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11899-016-0355-9","article-title":"Extranodal NK\/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.","volume":"1","author":"Porcu","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification.","volume":"13","author":"Chen","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1600-0609.2012.01796.x","article-title":"Clinical features and prognostic model for extranasal NK\/T-cell lymphoma.","volume":"8","author":"Suh","year":"2012","journal-title":"Eur J Haematol"},{"key":"7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-018-0687-0","article-title":"Treatment of localized extranodal NK\/T cell lymphoma, nasal type: a systematic review.","volume":"1","author":"Kim","year":"2018","journal-title":"J Hematol Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma.","volume":"2","author":"Yu","year":"2006","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type.","volume":"13","author":"Oguchi","year":"2018","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamaoncol.2016.5094","article-title":"Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer\/T-Cell Lymphoma.","volume":"3","author":"Yuan","year":"2017","journal-title":"JAMA Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ijrobp.2011.02.039","article-title":"Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK\/T-cell lymphoma.","volume":"8","author":"Yu","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1002\/cncr.30697","article-title":"The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States.","volume":"12","author":"Beriwal","year":"2017","journal-title":"Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.ijrobp.2010.10.040","article-title":"Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK\/T-cell lymphoma.","volume":"8","author":"Yu","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"14","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study.","volume":"12","author":"Zhang","year":"2015","journal-title":"Blood"},{"key":"15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ajh.25878","article-title":"Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.","volume":"9","author":"Qiao","year":"2020","journal-title":"Am J Hematol"},{"key":"16","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ejca.2015.07.009","article-title":"Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)\/T-cell lymphoma, nasal type.","volume":"5","author":"Koscielny","year":"2015","journal-title":"Eur J Cancer"},{"key":"17","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3892\/ol.2015.3327","article-title":"First-line combination of GELOX followed by radiation therapy for patients with stage IE\/IIE ENKTL: An updated analysis with long-term follow-up.","volume":"1","author":"Xia","year":"2015","journal-title":"Oncol Lett"},{"key":"18","doi-asserted-by":"publisher","first-page":"e21705","DOI":"10.1097\/MD.0000000000021705","article-title":"Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK\/T cell lymphoma: A prospective single-center phase II study.","volume":"9","author":"Zhang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijrobp.2018.05.046","article-title":"Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK\/T-Cell Lymphoma: The GREEN Study.","volume":"10","author":"Zhou","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"20","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.","volume":"2","author":"Ohshima","year":"2009","journal-title":"J Clin Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.10.011","article-title":"A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer\/T-Cell Lymphoma, Nasal-Type.","volume":"2","author":"Zhao","year":"2017","journal-title":"EBioMedicine"},{"key":"22","doi-asserted-by":"publisher","first-page":"85584","DOI":"10.18632\/oncotarget.11319","article-title":"Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I\/II extranodal NK\/T-cell lymphoma, nasal type (CISL-1008).","volume":"7","author":"Eom","year":"2016","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.","volume":"2","author":"Pyo","year":"2009","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.7150\/jca.24310","article-title":"A Multicenter Retrospective Comparison of Sequential versus Sandwich Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer\/T-Cell Lymphoma, Nasal Type.","volume":"9","author":"Yi","year":"2018","journal-title":"J Cancer"},{"key":"25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14737140.2019.1549992","article-title":"Defining the toxicity of current regimens for extranodal NK\/T cell lymphoma: a systematic review and metaproportion.","volume":"1","author":"Vinnikov","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"26","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1002\/cncr.26629","article-title":"Phase 2 trial of \"sandwich\" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T-cell lymphoma.","volume":"11","author":"Zou","year":"2012","journal-title":"Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.radonc.2009.08.045","article-title":"A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE\/IIE extranodal NK\/T-cell lymphoma, nasal type in the upper aerodigestive tract.","volume":"9","author":"Guo","year":"2009","journal-title":"Radiother Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1080\/10428194.2020.1811864","article-title":"Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.","volume":"6","author":"Horwitz","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"29","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1080\/10428194.2019.1599111","article-title":"Upfront radiation is essential for high-risk early-stage extranodal NK\/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.","volume":"6","author":"Yang","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14737140.2017.1344100","article-title":"L-Asparaginase for newly diagnosed extra-nodal NK\/T-cell lymphoma: systematic review and meta-analysis.","volume":"1","author":"Vinnikov","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"31","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.","volume":"12","author":"Chim","year":"2012","journal-title":"Blood"},{"key":"32","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1002\/cncr.26167","article-title":"Failure patterns and clinical implications in early stage nasal natural killer\/T-cell lymphoma treated with primary radiotherapy.","volume":"11","author":"Yu","year":"2011","journal-title":"Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2005-05-2056","article-title":"Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)\/II(E) extranodal NK\/T-cell lymphoma, nasal type.","volume":"10","author":"Kim","year":"2005","journal-title":"Blood"},{"key":"34","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.ejca.2005.03.010","article-title":"Extranodal nasal type NK\/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.","volume":"4","author":"Park","year":"2005","journal-title":"Eur J Cancer"},{"key":"35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0360-3016(02)02916-4","article-title":"Early stage nasal NK\/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality.","volume":"5","author":"Foo","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"36","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2012-06-435024","article-title":"Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK\/T-cell lymphoma patients receiving primary radiotherapy.","volume":"12","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"37","first-page":"1557","article-title":"Characteristics, Prognostic Factors, and Survival of Patients with NK\/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center Experience.","volume":"5","author":"Xia","year":"2019","journal-title":"Cancer Res Treat"},{"key":"38","doi-asserted-by":"publisher","first-page":"30317","DOI":"10.18632\/oncotarget.4505","article-title":"Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK\/T cell lymphoma in the era of asparaginase.","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"39","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/S2352-3026(15)00002-2","article-title":"Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer\/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.","volume":"2","author":"Lim","year":"2015","journal-title":"Lancet Haematol"},{"key":"40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijrobp.2007.05.073","article-title":"Early or up-front radiotherapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract.","volume":"7","author":"Lu","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"41","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1182\/bloodadvances.2020001852","article-title":"First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK\/T-cell lymphoma: a retrospective analysis from the CLCG.","volume":"4","author":"Qiao","year":"2020","journal-title":"Blood Adv"},{"key":"42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.31491\/APT.2020.12.045","article-title":"Optimal induction treatment regimens for extranodal NK\/T-cell lymphoma: lessons learned, challenges, and proposals.","volume":"2","author":"Wang","year":"2020","journal-title":"Aging Pathobiol Ther"},{"key":"43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00277-014-2244-4","article-title":"Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK\/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.","volume":"9","author":"Shi","year":"2015","journal-title":"Ann Hematol"},{"key":"44","first-page":"7034","article-title":"Selection of new immunotherapy targets for NK\/T cell lymphoma.","volume":"1","author":"Wu","year":"2020","journal-title":"Am J Transl Res"},{"key":"45","doi-asserted-by":"publisher","first-page":"e24824","DOI":"10.1097\/MD.0000000000024824","article-title":"Sustained remission of multi-line relapsed extranodal NK\/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.","volume":"10","author":"Chen","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.20892\/j.issn.2095-3941.2020.0400","article-title":"Updating targets for natural killer\/T-cell lymphoma immunotherapy.","volume":"1","author":"Zhang","year":"2021","journal-title":"Cancer Biol Med"},{"key":"47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41379-019-0392-8","article-title":"Immune subtyping of extranodal NK\/T-cell lymphoma: a new biomarker and an immune shift during disease progression.","volume":"3","author":"Kim","year":"2020","journal-title":"Mod Pathol"},{"key":"48","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"3","author":"Lister","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T01:47:27Z","timestamp":1668995247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":48,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,11,15]]}},"alternative-id":["204355","36326691"],"URL":"https:\/\/doi.org\/10.18632\/aging.204355","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}